Currently, the National Comprehensive Cancer Network (NCCN) recommends testing for the following gene mutations in patients with CRC, as they are potentially actionable biomarkers that can guide therapeutic considerations: BRAF and KRAS/NRAS mutations, HER2 amplifications, and microsatellite instability high (MSI-H)/mismatch repair (MMR) (Table 1) [29]. Here, ERBB2 is linked to colorectal carcinoma.